Table 4.
Phase 1 | Phase 2 | Total | p-value* | ||||
---|---|---|---|---|---|---|---|
Survival | n | % | n | % | n | % | |
TR deaths | 9 | 2 | 4 | 1 | 13 | 2 | 0.1242 |
ICU deaths | 106 | 26 | 67 | 21 | 173 | 24 | <0.001 |
Hospital deaths | 118 | 29 | 72 | 22 | 190 | 26 | <0.001 |
6 m deaths | 127 | 31 | 72 | 22 | 199 | 27 | <0.001 |
Unknown at 6 m | 179 | 44 | 39 | 12 | 218 | 30 | |
Total | 408 | 100 | 325 | 100 | 733 | 100 | |
6 month outcome | n | % | n | % | n | % | |
Favorable | 75 | 18 | 181 | 56 | 256 | 35 | <0.001 |
Unfavorable | 154 | 38 | 105 | 32 | 259 | 35 | |
Unknown | 179 | 44 | 39 | 12 | 218 | 30 | |
Grand Total | 408 | 100 | 325 | 100 | 733 | 100 |
Legend: *the tests were applied only on known values; 6 month outcome was measured by GOSE (Glasgow Outcome Scale extended) and dichotomized into favorable (GOSE score 7–8) and unfavorable (GOSE score 1–6) outcomes